To title: a novel mrna vaccine to prevent triple negative breast cancer IDIQ title: prevent cancer preclinical drug development program: preclinical efficacy and intermediate endpoint biomarkers
Ended Awarded Last action
- Contract number
- 75N91024F00002
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $760,552
Award facts
- Opportunity
-
- TORFP2024E01 Solicitation number
- Contract value 40% obligated
-
- $760,551.80 Current, with exercised options
- $1,886,811.80 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$4,328 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $764,880 |
About this award
The National Cancer Institute issued a $1.89 million delivery order to the University of Oklahoma Health Sciences Center on June 17, 2024, under the Preclinical Efficacy & Intermediate Endpoint Biomarkers IDIQ for development of a novel mRNA vaccine to prevent triple-negative breast cancer.
The parent IDIQ supports preclinical drug development research, including evaluation of efficacy and pharmacodynamic biomarkers for potential cancer preventive agents. Place of performance is Oklahoma City, OK. The delivery order is firm fixed price with an ultimate completion date of June 16, 2026. The University of Oklahoma Health Sciences Center self-performed all work in FY2024, reporting 84 contractor hours with no subcontractors.
Quick answers
Who was awarded contract 75N91024F00002?
75N91024F00002 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on June 17, 2024.
How much is contract 75N91024F00002 worth?
The government has obligated $760,552 on 75N91024F00002. Its potential value, with all options, is $1,886,812.
Is contract 75N91024F00002 an order under another contract?
Yes. 75N91024F00002 is a delivery order under 75N91024D00005, an indefinite delivery contract, on PRECLINICAL EFFICACY & INTERMEDIATE ENDPOINT BIOMARKERS IDIQ.
Was contract 75N91024F00002 competed?
The extent of competition for 75N91024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award